Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Recently, Liling Biopharmaceutical and Shanghai Pharmaceutical Group Biotherapy Technology Co., Ltd. ("SPG Biotherapy") held specialized discussions on the transformation of cell therapy technologies and the development of the health industry. Both parties delved into core issues, highly recognized each other's technical capabilities and resource advantages, and reached multiple consensuses on future cooperation directions and the potential applications of technology.Jointly Advance the Clinical Research of Universal NKT Cell Therapy Targeting Intracellular TargetsDuring the exchange, both parties focused on advancing the clinical development of universal NKT cell therapy targeting intracellular targets as the core agenda. This technology, a globally pioneering cell therapy, not only breaks through the limitations of cell membrane targets but also effectively addresses the industry pain points of high costs and long manufacturing cycles associated with current personalized cell therapies. It represents a key direction for achieving scalable applications in the field of cell therapy.Hua Jian, General Manager of Shanghai Pharmaceuticals Biotherapy, believes that Liling Biopharmaceutical has obvious innovative advantages in target discovery, molecular identification and optimization, and preclinical validation stages, which aligns closely with Shanghai Pharmaceuticals Biotherapy's goal of promoting the industrialization of cell therapy. Meanwhile, Shanghai Pharmaceuticals Biotherapy’s mature experience in clinical applications, compliance system building, and industrial implementation can provide critical support for technology transfer. The complementary strengths of both parties can accelerate the process of translating early discoveries into clinical applications, offering patients more treatment options. Dr. Wang Wenbo pointed out that in the field of cancer treatment, the patient's immune status must be considered. Tumor progression and long-term medication may damage the immune system, potentially reducing the efficacy of TCE drugs and the currently popular in vivo CAR-T therapies. However, exogenously supplemented universal NKT cells can not only directly kill and control tumors but also have the potential to partially restore the patient’s immune system, achieving two goals with one approach.
Exploring the Application of Leaimmunecenter® Technology Platform Developed by Liling Biopharmaceutical in B-cell Depletion Therapy and the Wellness FieldRegarding Liling Biopharmaceutical (Suzhou) Co., Ltd.'s self-developed immunomics solution platform: Leaimmunecenter®, both parties focused on discussing its clinical diagnostic value in B-cell depletion therapy. The platform precisely monitors the reconstitution process of B cells by detecting clones of different subtypes of BCR, providing a clinical auxiliary diagnostic tool for B-cell depletion therapies across all autoimmune diseases. Mr. Hua Jian highly endorsed the Leaimmunecenter® technology platform and pointed out that it will offer a differentiated technical solution for B-cell depletion therapy, with the potential to address the limitations and cost issues of flow cytometry and single-cell sequencing technologies, demonstrating broad clinical application value. Additionally, Mr. Hua believes that the Leaimmunecenter® platform, as a new precise immune assessment tool, can be integrated with the existing technical platforms of Shanghai Pharmaceutical Biotechnology to explore key areas in the large health industry, such as immune aging intervention. The precise immune capabilities of the Leaimmunecenter® platform can provide core technical support in this field, and in the future, more products that meet public health needs are expected to be developed. Meanwhile, the channel layout and brand influence of the large health industry will help transform this technology into marketable products, allowing the platform's value to serve public health more quickly and promote the development of the large health industry.This exchange has built a good communication bridge for the subsequent cooperation between the two parties. In the future, both sides will continue to promote the docking in areas such as technology research and development and clinical transformation, using cooperation to drive development, jointly advancing cell therapy technological innovation and the upgrading of the large health industry, and contributing to the development of the medical and health field.Source: Liling Biopharmaceutical
Mastering CAR-T Therapy, Stem Cell Therapy, and Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
